The DOI matches its Crossref record; 129 of the 129 references it cites were found in a registry or an index.
STING: a master regulator in the cancer-immunity cycle
Open accessAbstract
The aberrant appearance of DNA in the cytoplasm triggers the activation of cGAS-cGAMP-STING signaling and induces the production of type I interferons, which play critical roles in activating both innate and adaptive immune responses. Recently, numerous studies have shown that the activation of STING and the stimulation of type I IFN production are critical for the anticancer immune response. However, emerging evidence suggests that STING also regulates anticancer immunity in a type I IFN-independent manner. For instance, STING has been shown to induce cell death and facilitate the release of cancer cell antigens. Moreover, STING activation has been demonstrated to enhance cancer antigen presentation, contribute to the priming and activation of T cells, facilitate the trafficking and infiltration of T cells into tumors and promote the recognition and killing of cancer cells by T cells. In this review, we focus on STING and the cancer immune response, with particular attention to the roles of STING activation in the cancer-immunity cycle. Additionally, the negative effects of STING activation on the cancer immune response and non-immune roles of STING in cancer have also been discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intact TBK1 signaling is required for response to STING agonists, innate immune stimulatory molecules that mimic response to cytosolic DNA, which have been shown to limit tumour growth alone or in combination with cancer immunotherapy 46-48 .”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [46]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pattern Recognition Receptors and Inflammation
Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
Sun, L., Wu, J., Du, F., Chen, X., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1232458 · Cited by 4,996
STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling
Ishikawa, H., & Barber, G. N. (2008) · Nature · doi:10.1038/nature07317 · Cited by 3,576
STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity
Ishikawa, H., Ma, Z., & Barber, G. N. (2009) · Nature · doi:10.1038/nature08476 · Cited by 2,759
Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I., Conway, S. J., Marshall, B., Brown, C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,585
Cyclic GMP-AMP Is an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA
Wu, J., Sun, L., Chen, X., Du, F., Shi, H., Chen, C., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1229963 · Cited by 2,541
The PD‐1 pathway in tolerance and autoimmunity
Francisco, L. M., Sage, P. T., & Sharpe, A. H. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00923.x · Cited by 2,300
Murphy, K., & Weaver, C. (2016) · W.W. Norton eBooks · doi:10.1201/9781315533247 · Cited by 2,258
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Cited by
Exploring the next generation of antibody–drug conjugates
Tsuchikama, K., Anami, Y., Ha, S. Y. Y., & Yamazaki, C. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00850-2 · Cited by 659
Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy
Garland, K. M., Sheehy, T. L., & Wilson, J. T. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00750 · Cited by 357
Cytokinocytes: the diverse contribution of keratinocytes to immune responses in skin
Jiang, Y., Tsoi, L. C., Billi, A. C., Ward, N. L., Harms, P. W., Zeng, C., Maverakis, E., Kahlenberg, J. M., & Gudjonsson, J. E. (2020) · JCI Insight · doi:10.1172/jci.insight.142067 · Cited by 348
Epigenetic modulation of antitumor immunity for improved cancer immunotherapy
Dai, E., Zhu, Z., Wahed, S., Qu, Z., Storkus, W. J., & Guo, Z. S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01464-x · Cited by 328
Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy
Zheng, J., Mo, J., Zhu, T., Zhuo, W., Yi, Y., Hu, S., Yin, J., Zhang, W., Zhou, H., & Liu, Z. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01250-1 · Cited by 326
Metadata
- Authors
- Zhu, Y., An, X., Zhang, X., Qiao, Y., Zheng, T., & Li, X.
- Affiliations
- Harbin Medical University (CN)
- Corresponding author
- Zheng, Tongsen
- Li, Xiaobo
- Venue
- Molecular Cancer
- Published
- 2019-11-04
- Volume
- 18
- Issue
- 1
- Pages
- 152-152
- ISSN
- 1476-4598 (ISSN-L)
- PMC
- PMC6827255
- OpenAlex
- W2988506530
- Cited by
- 431
- References
- 129
- Citations by year
- 2026: 47 · 2025: 82 · 2024: 70 · 2023: 78 · 2022: 67 · 2021: 56 · 2020: 31
- FWCI
- 3.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- Molecular Cancer (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Scientific Foundation of China (NO. 81872435, NO. 81672930, No. 81871976)
- Fok Ying Tung Education Foundation (No. 151037)
- National Youth Talent Support Program (W03070060)
- Academician Yu Weihan Outstanding youth foundation of Harbin Medical University
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- STING, cancer-immunity cycle, type I interferon, cytosolic DNA sensing, cancer immunotherapy, cancer cell death, tumor immunosuppression
- MeSH terms
- STING Protein, Animals, Antigens, Neoplasm, Disease Susceptibility, Humans, Immunity, Innate, Immunotherapy, Interferon Type I, Membrane Proteins, Neoplasms, Signal Transduction, Gene Expression Regulation, Neoplastic, Immunomodulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: STING: a master regulator in the cancer-immunity cycle. https://app.cochat.ai/papers/10.1186/s12943-019-1087-y
- The paper
- Zhu, Y., An, X., Zhang, X., Qiao, Y., Zheng, T., & Li, X. (2019). STING: a master regulator in the cancer-immunity cycle. Molecular Cancer. https://doi.org/10.1186/s12943-019-1087-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.